Scientists Discover Unique Antibodies That Can Neutralize Wide Range of SARS Coronaviruses

A team of scientists from the VIB-UGent Center for Medical Biotechnology has made a groundbreaking discovery, identifying a unique class of small antibodies that can strongly protect against a wide range of SARS coronaviruses, including SARS-CoV-1 and various SARS-CoV-2 variants. These antibodies target a highly conserved site at the base of the virus's spike protein, effectively clamping it shut and preventing the virus from infecting cells. The findings, published in Nature Communications, offer a promising route to developing broad-spectrum antiviral treatments that could remain effective against future viral variants.

Key Takeaways:

• The unique antibodies identified by the research team are capable of strongly neutralizing a broad panel of SARS coronaviruses, including SARS-CoV-1 and various SARS-CoV-2 variants.
• These antibodies target a poorly exposed, highly conserved region at the base of the virus's spike protein, effectively clamping it shut and preventing the virus from infecting cells.
• The antibodies act like a molecular clamp, locking the spike protein in its original shape and preventing it from unfolding into the form the virus needs to infect cells.
• The research team used a llama (Winter) to generate single-domain antibodies, also known as VHHs or nanobodies, which are much smaller than the antibodies generated by most animals, including humans.
• The antibodies showed strong protection against infection in lab animals, even at low doses, and were found to be effective against a range of SARS coronaviruses.
• The discovery of these unique antibodies offers a promising route to developing broad-spectrum antiviral treatments that could remain effective against future viral variants.

Statistics:

• The researchers identified several llama antibodies that strongly neutralized a broad panel of SARS coronaviruses.
• The antibodies are capable of providing strong protection against infection in lab animals, even at low doses.
• The research team found that the virus struggled to evolve resistance to the antibodies, producing only rare escape variants that were much less infectious.

Sources:

• Ultrapotent SARS coronavirus-neutralizing single-domain antibodies that clamp the spike at its base. De Cae, S., Van Molle, I., van Schie, L. et al. Nat Communications, 2025. DOI: https://doi-org.sdpl.idm.oclc.org/10.1038/s41467-025-60250-1
• Research was made possible with financial support from the Research Foundation - Flanders (FWO), EOS, EU Horizon 2021, and Exevir.